title: Diabetic dyslipidemia.
abstract: Type 2 diabetes mellitus is associated with a markedly increased risk of cardiovascular disease. A complex dyslipidemia, which is an integral part of the underlying insulin resistance in this group, is a key to this increased risk. Increased secretion of VLDL from the liver is a central feature of dyslipidemia and is linked significantly to the low HDL and abnormal LDL that are also present. A number of physiologic and pharmacologic approaches are available and should be used aggressively to treat diabetic dyslipidemia.
authors.affiliation: Department of Medicine, College of Physicians and Surgeons of Columbia University, PH 10-305, 630 West 168th Street, New York, NY 10032, USA.
authors.forename: Tina J
authors.initials: TJ
authors.lastname: Chahil
authors.forename: Henry N
authors.initials: HN
authors.lastname: Ginsberg
mesh_terms: D002318:Cardiovascular Diseases / Q000517:prevention & control; D002914:Chylomicrons / Q000378:metabolism; D048909:Diabetes Complications; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications*; D008074:Lipoproteins / Q000378:metabolism; D008075:Lipoproteins, HDL / Q000378:metabolism / Q000502:physiology; D008077:Lipoproteins, LDL / Q000097:blood / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000096:biosynthesis / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D010316:Particle Size; D012307:Risk Factors
chemical_list: D002914:Chylomicrons; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL